Idiopathic Angioedema: Current Challenges
| Autor: | Laurence Bouillet, Aude Belbézier, Alexis Bocquet |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Pulmonary and Respiratory Medicine
Functional assay medicine.medical_specialty biology Angioedema business.industry Bradykinin Omalizumab Idiopathic angioedema Dermatology C1-inhibitor chemistry.chemical_compound chemistry Icatibant biology.protein Etiology Immunology and Allergy Medicine medicine.symptom business medicine.drug |
| Zdroj: | Journal of Asthma and Allergy. 13:137-144 |
| ISSN: | 1178-6965 |
| DOI: | 10.2147/jaa.s205709 |
| Popis: | The etiological diagnosis of isolated recurrent angioedema poses problems because it must often be done urgently. Angioedema secondary to nonspecific mast cell activation (MC-AE) is the most frequent form and is usually mild. Bradykinin mediated angioedema (BK-AE) is rarer but potentially fatal in the absence of the correct treatment. Few biological markers exist. The C1-inhibitor (C1-inh) functional assay can exclude AE due to C1-inh deficiency. Genetic diagnoses of hereditary AE due to abnormal C1-inh AE have progressed with four currently known mutations. However, determining the physiopathological mechanism leading to some isolated AE cases is sometimes very difficult. In such cases, therapeutic tests are then the only solution: antihistamines at high doses and omalizumab for suspected MC-AE, icatibant for suspected AE-BK. Identifying new markers would be a great help. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|